Creative Medical Technology Holdings, Inc. Common Stock
CELZCreative Medical Technology Holdings, Inc. (CELZ) is a biotechnology company focused on developing regenerative medicine therapies, particularly in the field of stem cell and regenerative medicine. The company aims to create innovative solutions for medical conditions through the application of cellular technology and regenerative approaches.
Company News
Creative Medical Technology Holdings (NASDAQ: CELZ) announced agreements to exercise existing warrants for $4.5 million in gross proceeds. The company will issue new unregistered warrants to purchase up to 5.58 million shares at $1.60 per share, pending shareholder approval. Net proceeds will be used for working capital and general corporate purp...
Creative Medical Technology Holdings (NASDAQ: CELZ) announced the advancement of Project PHOENIX into a nationwide virtual data collection phase targeting at least 1,000 U.S. veterans exposed to burn pits and toxic hazards. The AI-driven platform leverages mobile-app technology and field-capable logistics to collect exposure history, health data,...
Creative Medical Technology Holdings announced promising mid-term follow-up data from its StemSpine® pilot study, which demonstrated a substantial reduction in opioid dependency and significant improvements in pain levels and functional mobility for chronic lower back pain patients.
PHOENIX, June 24, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced that it has successfully generat...
Shares of HighPeak Energy, Inc. (NASDAQ: HPK) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter revenue results. HighPeak Energy posted GAAP earnings of 66 cents per share, versus market estimates of 65 cents per share. The company’s quarterly sales came in at $301.153 million versus expecta...
